Literature DB >> 391256

Decreased plasma protein binding of phenytoin in patients on valproic acid.

R Dahlqvist, O Borgå, A Rane, Z Walsh, F Sjöqvist.   

Abstract

1 Plasma protein binding of phenytoin and of valproic acid were measured in ten epileptic patients on this drug combination. Ten other epileptics not on valproic acid served as controls. All patients had normal kidney function. 2 The measured free fraction of phenytoin among the patients on valproic acid ranged from 12.5 to 23.2% and after recalculation to a plasma albumin level of 45 g/l from 12.5 to 20.0 (median 15.4%). This differed significantly (P = 0.002, Mann- Whitney U-test) from the control patients where the normalized values ranged from 9.9 to 13.9% with a median value of 11.8%. 3 The measured free fractions of phenytoin and of valproic acid showed a significant correlation which, however, was due to the quantitative relation between the degree of binding of both these drugs and the concentration of plasma albumin. There was no discernable relation in this material between the free concentration of valproic acid and the free fraction of phenytoin. 4 It is concluded that patients on combined treatment with phenytoin and valproic acid have an unpredictably raised free fraction of phenytoin. This drug interaction therefore can complicate the important plasma level monitoring of phenytoin in epileptic patients unless the free concentration of this drug can be analysed or estimated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 391256      PMCID: PMC1429898          DOI: 10.1111/j.1365-2125.1979.tb01042.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Effect of sodium valproate on plasma protein binding of diphenylhydantoin.

Authors:  P N Patsalos; P T Lascelles
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-06       Impact factor: 10.154

2.  New direct micro-method for determination of valproic acid in serum by gas chromatography.

Authors:  C Jakobs; M Bojasch; F Hanefeld
Journal:  J Chromatogr       Date:  1978-11-01

3.  Disposition of valproic acid in patients with liver disease.

Authors:  U Klotz; T Rapp; W A Müller
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

4.  Valproate may lower serum-phenytoin.

Authors:  A Bardy; R Hari; R Lehtovaara; H Majuri
Journal:  Lancet       Date:  1976-12-11       Impact factor: 79.321

5.  Valproic acid in epilepsy: clinical and pharmacological effects.

Authors:  R H Mattson; J A Cramer; P D Williamson; R A Novelly
Journal:  Ann Neurol       Date:  1978-01       Impact factor: 10.422

6.  Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.

Authors:  R Gugler; G Mueller
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

7.  Valproic acid: interaction with other anticonvulsant drugs.

Authors:  B J Wilder; L J Willmore; J Bruni; H J Villarreal
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

8.  Sodium valproate in the treatment of intractable seizure disorders: a clinical and electroencephalographic study.

Authors:  D J Adams; H Luders; C Pippenger
Journal:  Neurology       Date:  1978-02       Impact factor: 9.910

9.  Plasma protein binding interaction between phenytoin and valproic acid in vitro.

Authors:  A Monks; S Boobis; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

10.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

View more
  16 in total

Review 1.  What is the true clinical significance of plasma protein binding displacement interactions?

Authors:  L N Sansom; A M Evans
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  Interaction between vigabatrin and phenytoin.

Authors:  E M Rimmer; A Richens
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  Therapeutic drug monitoring.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

Review 5.  Protein binding displacement interactions and their clinical importance.

Authors:  J C McElnay; P F D'Arcy
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

6.  Free sodium valproate monitoring.

Authors:  E J Roman; P Ponniah; J B Lambert; N Buchanan
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.

Authors:  F J Rowell; S M Hui; A F Fairbairn; D Eccleston
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Effect of valproate on free plasma phenytoin concentrations.

Authors:  L M Tsanaclis; J Allen; E Perucca; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

10.  Should we routinely measure free plasma phenytoin concentration?

Authors:  E M Rimmer; D C Buss; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.